Rachele Penati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rachele Penati has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Aiuti
Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
2 shared publications - Anna Odone
Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy
2 shared publications - Francesca Fumagalli
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), 20132 Milan, Italy
2 shared publications Maria Ester Bernardo
San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy
2 shared publications- Riccardo Vecchio
Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100 Pavia, Italy
2 shared publications - Roberto Gatto
Centro Studi So Wen ETS, 20146 Milano, Italy
2 shared publications
Latest Publications
- Open Access
- 24 February 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (3) , 131
Correction: Penati et al. High Outcome-Reporting Bias in Randomized-Controlled Trials of Acupuncture for Cancer Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Epidemiological Study. Curr. Oncol. 2025, 32, 462
The authors inadvertently omitted to indicate a second affiliation of Anna Odone in the original publication
- 24 February 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (3) , 131
Open AccessCorrection: Penati et al. High Outcome-Reporting Bias in Randomized-Controlled Trials of Acupuncture for Cancer Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Epidemiological Study. Curr. Oncol. 2025, 32, 462
The authors inadvertently omitted to indicate a second affiliation of Anna Odone in the original publication
- Open Access
- 15 August 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (8) , 462
High Outcome-Reporting Bias in Randomized-Controlled Trials of Acupuncture for Cancer Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Epidemiological Study
Selective outcome-reporting bias refers to the selective reporting of a subset of study findings. This methodological limitation may occur in cancer-related acupuncture studies, where valid empirical studies on psychometric performance are still lacking. We assessed the risk of selective outcome reporting bias in studies published in English that were included in a systematic review on acupuncture for preventing cancer chemotherapy-induced nausea and vomiting. For each study, we searched for registry availability and, if present, assessed its validity. We described each study outcome (nausea, vomiting, or both) according to the following seven items: type of outcome, domain, specific measurement, specific metric, type of data, methods of aggregation, and timepoint unit and time. Eleven studies published between 1987 and 2019 in English were evaluated. Only four (36%) had a registry, of which only two were prospective and therefore considered valid. Discrepancies were found in the specific measurement of the outcome in two studies and in the specific metric. In many other cases, discrepancies were not evaluable due to missing information. No study reported complete outcomes as planned in the published protocol. Communication about the importance of prospective trial registration, including outcome details, should be enforced to reduce the risk of selective outcome reporting bias in oncology acupuncture studies.
- 15 August 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (8) , 462
Open AccessHigh Outcome-Reporting Bias in Randomized-Controlled Trials of Acupuncture for Cancer Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Epidemiological Study
Selective outcome-reporting bias refers to the selective reporting of a subset of study findings. This methodological limitation may occur in cancer-related acupuncture studies, where valid empirical studies on psychometric performance are still lacking. We assessed the risk of selective outcome reporting bias in studies published in English that were included in a systematic review on acupuncture for preventing cancer chemotherapy-induced nausea and vomiting. For each study, we searched for registry availability and, if present, assessed its validity. We described each study outcome (nausea, vomiting, or both) according to the following seven items: type of outcome, domain, specific measurement, specific metric, type of data, methods of aggregation, and timepoint unit and time. Eleven studies published between 1987 and 2019 in English were evaluated. Only four (36%) had a registry, of which only two were prospective and therefore considered valid. Discrepancies were found in the specific measurement of the outcome in two studies and in the specific metric. In many other cases, discrepancies were not evaluable due to missing information. No study reported complete outcomes as planned in the published protocol. Communication about the importance of prospective trial registration, including outcome details, should be enforced to reduce the risk of selective outcome reporting bias in oncology acupuncture studies.
- Open Access
- 1 April 2025
- Published by SAGE Publications in Advances in Rehabilitation Science and Practice
- Vol. 14
Heart Rate Variability as a Possible Biomarker of Cognitive-Motor Integration in Post-Stroke Patients
Heart Rate Variability (HRV) refers to variation in time intervals between consecutive heartbeats, indicating autonomic nervous system’s control over the heart. Time and frequency analysis of HRV could serve as predictors for severity and functional outcome in stroke. Aim of this study is to verify if HRV, measured during cognitive and sensorimotor upper limb (UL) tasks, can be used as a biomarker of cognitive-motor interaction in post-stroke patients. Forty-six patients with unilateral brain injury following stroke were enrolled: 27 (58.7%) ischemic, 19 hemorrhagic, 24 (52.2%) subacute (<6 months), and 22 chronic. Mean age at evaluation was 61 years. Right side was affected in 16 subjects (34.8%). Each patient underwent HRV recording in the following conditions: (1) Rest (5 minutes); (2) Visuomotor simulation training of the affected upper limb (UL) using Dessintey IVS3 (DE, 5 minutes); (3) Motor Imagery of the affected UL (MI, 5 minutes). UL functional outcome measures were collected for both affected and less affected sides. All patients showed reduced HRV in time and frequency domains and sympathetic tone predominance at rest. During DE and MI, a significant reduction in time domain was observed. In frequency domains, low frequency decreases during DE, with parasympathetic tone predominance. In the subgroup analyses for lesion side, only right hemiparetic patients showed parasympathetic predominance during mental tasks of the upper limb (DE and MI. No correlation was found between HRV parameters and UL functional scales. Different HRV response in time and frequency domains to mental task was observed between right and left hemiparetic subjects. This could be explained by different anatomical-functional substrates between right and left hemisphere and could reflect different behaviors during UL cognitive-motor tasks. HRV parameters were not correlated with clinical functional assessment scales, likely meaning that they possible exploring different domains.
- 1 April 2025
- Published by SAGE Publications in Advances in Rehabilitation Science and Practice
- Vol. 14
Open AccessHeart Rate Variability as a Possible Biomarker of Cognitive-Motor Integration in Post-Stroke Patients
Heart Rate Variability (HRV) refers to variation in time intervals between consecutive heartbeats, indicating autonomic nervous system’s control over the heart. Time and frequency analysis of HRV could serve as predictors for severity and functional outcome in stroke. Aim of this study is to verify if HRV, measured during cognitive and sensorimotor upper limb (UL) tasks, can be used as a biomarker of cognitive-motor interaction in post-stroke patients. Forty-six patients with unilateral brain injury following stroke were enrolled: 27 (58.7%) ischemic, 19 hemorrhagic, 24 (52.2%) subacute (<6 months), and 22 chronic. Mean age at evaluation was 61 years. Right side was affected in 16 subjects (34.8%). Each patient underwent HRV recording in the following conditions: (1) Rest (5 minutes); (2) Visuomotor simulation training of the affected upper limb (UL) using Dessintey IVS3 (DE, 5 minutes); (3) Motor Imagery of the affected UL (MI, 5 minutes). UL functional outcome measures were collected for both affected and less affected sides. All patients showed reduced HRV in time and frequency domains and sympathetic tone predominance at rest. During DE and MI, a significant reduction in time domain was observed. In frequency domains, low frequency decreases during DE, with parasympathetic tone predominance. In the subgroup analyses for lesion side, only right hemiparetic patients showed parasympathetic predominance during mental tasks of the upper limb (DE and MI. No correlation was found between HRV parameters and UL functional scales. Different HRV response in time and frequency domains to mental task was observed between right and left hemiparetic subjects. This could be explained by different anatomical-functional substrates between right and left hemisphere and could reflect different behaviors during UL cognitive-motor tasks. HRV parameters were not correlated with clinical functional assessment scales, likely meaning that they possible exploring different domains.
- Open Access
- 29 January 2018
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 53 (7) , 913-917
Use of Defibrotide to help prevent post-transplant endothelial injury in a genetically predisposed infant with metachromatic leukodystrophy undergoing hematopoietic stem cell gene therapy
- 29 January 2018
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 53 (7) , 913-917
Open AccessUse of Defibrotide to help prevent post-transplant endothelial injury in a genetically predisposed infant with metachromatic leukodystrophy undergoing hematopoietic stem cell gene therapy
- Open Access
- 30 May 2017
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 40 (4) , 543-554
Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I
Lysosomal storage diseases (LSDs) are rare inherited metabolic disorders characterized by a dysfunction in lysosomes, leading to waste material accumulation and severe organ damage. Enzyme replacement therapy (ERT) and haematopoietic stem cell transplant (HSCT) have been exploited as potential treatments for LSDs but pre‐clinical and clinical studies have shown in some cases limited efficacy. Intravenous ERT is able to control the damage of visceral organs but cannot prevent nervous impairment. Depending on the disease type, HSCT has important limitations when performed for early variants, unless treatment occurs before disease onset. In the attempt to overcome these issues, gene therapy has been proposed as a valuable therapeutic option, either ex vivo, with target cells genetically modified in vitro, or in vivo, by inserting the genetic material with systemic or intra‐parenchymal, in situ administration. In particular, the use of autologous haematopoietic stem cells (HSC) transduced with a viral vector containing a healthy copy of the mutated gene would allow supra‐normal production of the defective enzyme and cross correction of target cells in multiple tissues, including the central nervous system. This review will provide an overview of the most recent scientific advances in HSC‐based gene therapy approaches for the treatment of LSDs with particular focus on metachromatic leukodystrophy (MLD) and mucopolysaccharidosis type I (MPS‐I).
- 30 May 2017
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 40 (4) , 543-554
Open AccessGene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I
Lysosomal storage diseases (LSDs) are rare inherited metabolic disorders characterized by a dysfunction in lysosomes, leading to waste material accumulation and severe organ damage. Enzyme replacement therapy (ERT) and haematopoietic stem cell transplant (HSCT) have been exploited as potential treatments for LSDs but pre‐clinical and clinical studies have shown in some cases limited efficacy. Intravenous ERT is able to control the damage of visceral organs but cannot prevent nervous impairment. Depending on the disease type, HSCT has important limitations when performed for early variants, unless treatment occurs before disease onset. In the attempt to overcome these issues, gene therapy has been proposed as a valuable therapeutic option, either ex vivo, with target cells genetically modified in vitro, or in vivo, by inserting the genetic material with systemic or intra‐parenchymal, in situ administration. In particular, the use of autologous haematopoietic stem cells (HSC) transduced with a viral vector containing a healthy copy of the mutated gene would allow supra‐normal production of the defective enzyme and cross correction of target cells in multiple tissues, including the central nervous system. This review will provide an overview of the most recent scientific advances in HSC‐based gene therapy approaches for the treatment of LSDs with particular focus on metachromatic leukodystrophy (MLD) and mucopolysaccharidosis type I (MPS‐I).